Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor Conferences
Reviva Pharmaceuticals (NASDAQ: RVPH) announced that its Founder and CEO, Laxminarayan Bhat, will participate in the 5th Annual Neuroscience Innovation Forum on March 23, 2022, and BIO-Europe Spring from March 28 to 31, 2022. Both events will feature corporate presentations available on demand, with opportunities for one-on-one meetings. Reviva focuses on developing therapies for CNS, cardiovascular, metabolic, and inflammatory diseases, with notable drug candidates RP5063 and RP1208. The company emphasizes its commitment to addressing significant unmet medical needs.
- None.
- None.
- 5th Annual Neuroscience Innovation Forum -
- BIO-Europe Spring® 2022 -
CUPERTINO, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following conferences in March and invites investors to participate in virtual one-on-one meetings. Please see additional details below:
| 5th Annual Neuroscience Innovation Forum (NIF) – Registration Link | |
| Panel: Advances in Neuropsychiatry Panel | |
| Wednesday, March 23rd at 9:00am ET | |
| Corporate Presentation Details: Available on demand | |
| Location: Solely Digital Format | |
| Speaker: Laxminarayan Bhat, Founder & CEO of Reviva | |
| One-on-One meeting requests available using the Event Partnering & Networking System | |
| BIO-Europe Spring® – Registration Link | |
| Monday, March 28th - Thursday, March 31st | |
| Corporate Presentation Details: Available on demand | |
| Location: Virtual & Basel, Switzerland | |
| Presenter: Laxminarayan Bhat, Founder & CEO of Reviva | |
| One-on-One meeting requests available using partneringONE® | |
About Reviva
Reviva is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and RP1208 in the United States (U.S.), Europe, and several other countries.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company’s RECOVER Phase 3 trial, product development, clinical and regulatory timelines and expenses, market opportunity, ability to raise sufficient funding, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
What is Reviva Pharmaceuticals planning for March 2022?
Who will represent Reviva Pharmaceuticals at the conferences?
What drug candidates is Reviva Pharmaceuticals currently developing?
Where can I find more information about Reviva Pharmaceuticals' conferences?
What areas does Reviva Pharmaceuticals focus on?
